Investigation of the Therapeutic Effects of Chloroquine in Adriamycin-Induced Hepatotoxicity

Basit Öğe Kaydı
dc.authoridCEYLAN, TAYFUN/0000-0002-0917-0378
dc.contributor.authorAkin, Ali Tugrul
dc.contributor.authorKaymak, Emin
dc.contributor.authorOzturk, Emel
dc.contributor.authorKarabulut, Derya
dc.contributor.authorKuloglu, Nurhan
dc.contributor.authorCeylan, Tayfun
dc.contributor.authorToluk, Ayse
dc.date.accessioned2024-11-07T13:35:12Z
dc.date.available2024-11-07T13:35:12Z
dc.date.issued2021
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractThe aim of this study is to investigate the therapeutic effects of Chloroquine (CLQ) against Adriamycin (ADR) induced hepato-toxicity. ADR is a chemotherapeutic agent used in the treatment of many cancer types, but it causes hepatotoxicity. CLQ is used as an anti-inflammatory drug in the treatment of malaria, rheumatoid arthritis, and pneumonia caused by Covid-19. Rats were divided into four groups: Control group, ADR group (2 mg/kg Adriamycin, one in three days for 30 days, i.p.), CLQ group (50 mg/kg Chloroquine, per day for 30 days, i.p.), ADR+CLQ (2 mg/kg Adriamycin, one in three days for 30 days, i.p. and 50 mg/kg Chloroquine, per day for 30 days, i.p.). Animals were sacrificed, and liver tissues were extracted for further examinations. Histopathological changes in liver tissues were scored and IL-17 immunostaining was performed to determine the expression levels among experimental groups. Bodyweights in the ADR group decreased significantly compared to the Control group and CLQ group. Furthermore, bodyweight in ADR+CLQ group was significantly higher compared to ADR group. The histopathological score was significantly higher in ADR group when compared to Control and CLQ group while CLQ administrations reduced the damage induced by ADR in the ADR+CLQ group. IL-17 immunoreactivity was considerably increased in the ADR group. On the other hand, IL-17 expressions of ADR+CLQ were substantially less compared to ADR group. We suggest that CLQ can be used as a therapeutic agent to reduce the detrimental effects of ADR, thanks to its anti-inflammatory properties.
dc.identifier.doi10.2478/ebtj-2021-0003
dc.identifier.endpage23
dc.identifier.issn2564-615X
dc.identifier.issue1
dc.identifier.startpage17
dc.identifier.urihttps://doi.org/10.2478/ebtj-2021-0003
dc.identifier.urihttps://hdl.handle.net/11480/16371
dc.identifier.volume5
dc.identifier.wosWOS:000613126700004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherSciendo
dc.relation.ispartofEurobiotech Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectAdriamycin
dc.subjectchloroquine
dc.subjectIL-17
dc.subjectliver damage
dc.titleInvestigation of the Therapeutic Effects of Chloroquine in Adriamycin-Induced Hepatotoxicity
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu